FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Endo Withdraws Opana Painkiller From Market at FDA’s Request

July 10, 2017
A A

Endo will withdraw Opana ER from the market, following an FDA request in June.

The agency made the request after determining the benefits of the extended-release opioid painkiller no longer outweighed the risks of its abuse.

Postmarket data showed a change in the main route of abuse of Opana ER (oxymorphone hydrochloride) from snorting to intravenous injection, after the pill was reformulated with deterrent properties.

View today's stories